Moderna and CEPI expand Ebola vaccine
Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The expanded collaboration between Moderna>>> and Coalition for Epidemic Preparedness Innovations>>> for a Bundibugyo ebolavirus vaccine is positive for Moderna's>>> stock, demonstrating its commitment to addressing global health threats and leveraging its mRNA platform. The funding from Coalition for Epidemic Preparedness Innovations>>> de-risks the early development stages, potentially leading to future revenue streams for Moderna>>> if the vaccine progresses successfully.
Moderna>>> announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations>>> (CEPI) to develop a potential vaccine against Bundibugyo ebolavirus (BDBV). CEPI has committed up to $50 million to support preclinical development and Phase 1 clinical testing, as well as parallel manufacturing activities. This funding aims to accelerate the program into large-scale Phase 2/3 trials. The vaccine candidate utilizes Moderna's>>> mRNA platform, building on its existing research in filoviruses. The collaboration is a strategic move to strengthen global readiness against future Ebola outbreaks, especially given the current BDBV outbreak, which has been declared a Public Health Emergency of International Concern by the World Health Organization>>> and a Public Health Emergency of Continental Security by United States — Centers for Disease Control and Prevention>>>.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard